在实验性结肠炎中,通过IL-6siRNA和甲酸共载的三甲基基托桑纳米颗粒向炎症和氧化应激
Dana Hales1, Alina Porfire1, Diana Cenariu2
1Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, University of Medicine and Pharmacy "Iuliu Hațieganu" Cluj-Napoca 400012 Cluj-Napoca, Romania.
International journal of pharmaceutics
|December 6, 2025
概括
这项研究开发了结合短干扰RNA (siRNA) 和酸 (AA) 的新型纳米颗粒来治疗大肠炎. 在小鼠中,siRNA_AA NPs有效降低了炎症并促进了组织修复,提供了一个有前途的新疗法策略.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 胃肠病学 胃肠病学
背景情况:
- 大肠炎的治疗是具有挑战性的,因为炎症和氧化应激.
- 短干扰RNA (siRNA) 在向促炎细胞因子方面表现有前途.
- 抗氧化剂可以提高炎症条件下的治疗结果.
研究的目的:
- 开发针对结肠的纳米颗粒,共同提供IL-6siRNA和甲酸 (AA).
- 在大肠炎模型中评估siRNA_AANP的协同抗炎和抗氧化作用.
- 为了研究siRNA_AA NPs在患有诱导性大肠炎的小鼠中的治疗疗效.
主要方法:
- 三甲基基多 (TMC) 纳米粒子 (NP) 的制备和表征.
- 评估影响NP质量的配方因素.
- 在诱导性大肠炎的小鼠模型中体内测试siRNA_AANP,与对照和普雷迪尼索隆进行比较.
主要成果:
- siRNA_AA NPs显示了IL-6和IL-1β的显著基因沉默.
- siRNA_AA NPs的治疗效果超过了普雷尼索隆的治疗效果.
- 组织病理学分析证实了siRNA_AA NP治疗小鼠的组织修复和减少损伤.
结论:
- 针对结肠的siRNA_AANP在治疗诱导性结肠炎方面是有效的.
- 结合的抗炎和抗氧化方法提供了协同的治疗效益.
- 这一战略通过准关键的病理生理机制,为治疗大肠炎提供了一种新的方法.
关键词:
亚斯科布酸是一种亚斯科布酸.实验性结肠炎是一种实验性结肠炎.纳米颗粒 纳米颗粒三甲基基三甲基基三甲基基三甲基基三甲基基三甲基基三甲基基三甲基基三甲基基三甲基基三甲基基三甲基基三甲基基三甲基基三甲基基三甲基基三甲基基三甲基基三甲基三甲基三甲基基三甲基基三甲基三甲基三甲基三甲基三甲基基三甲基基三甲基基三甲基基三甲基基三甲基三甲基基三甲基基三甲基基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲基三甲三甲三甲三甲三甲三甲三甲三甲三甲三甲三甲三甲三甲三甲三甲三甲三甲三甲三甲三甲三甲三甲三甲三甲三甲三甲三甲三甲四siRNA 是一个RNA.更多相关视频
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
431
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
431
01:29Inflammatory Bowel Disease IV: Pharmacological Management
450
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
450
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
461
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
461
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
617
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
617